Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Revenio Group Oyj, Q3'26

By Inderes11/12/2026, 1:00 PM
Revenio Group

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Jukka Kainulainen
00:01 - 17:36

Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on the call as well. Today's agenda is as follows. I am starting by recapping the Q3 from a financial summary point of view. Then, let's also spend a bit of time on where we have been focusing during Q3 and how things like integration and other topics have been progressing throughout the quarter. Jukka is going to continue by going through the financials. Then also, of course, the guidance. Then we move for the Q&A. Q3. In all aspects, this is a historic quarter for Revenio. So during Q3, we have doubled our scale. We have kicked off the integration, of course. And if we look from the pure numbers perspective, net sales were 58.8 million during the Q3. If you look at the reported numbers perspective compared to old Revenio, the growth is roughly a bit less than 130%. And we have also been increasing the transparency. Regarding reporting, we are providing more detail on our region-based numbers. We had an extremely strong growth in our largest region, which is EMEA and LatAm, ending up at 34.3 million. If you look at the other regions like APAC, those remained soft during Q3. And then we have been focusing on the USA. Our organization changed, especially on the sales and marketing side. I will come back to that later. So we had a slight decline year on year if we compare to the pro forma in the USA. But I will return to that later. And the reason for that is that we reorganized the entire sales and marketing organization in order to be able to provide long-term sustainable growth. Also in the USA, adjusted EBITDA was 8.7 million. So compared to last year. So that's a 30% increase. And also, we have become stronger in terms of our cash flow. 5.5 million up from 3 million. And then we are advancing the integration as planned, on an even faster schedule than what we originally planned. So far, we have been able to secure, on a run-rate basis, 25% of the targeted 20 million EBITDA uplift. Regarding the Q3, the focus of the organization has been really building the base for long-term sustainable growth. If we look back at the old Revenio where we were selling tonometers, fundus imaging devices, perimeters, probes, and software solutions like Icare ILLUM. Now the company is totally different, and the priorities are totally different. During Q3, we have, of course, clarified the new combined company strategy. We communicated that during the CMD. And if you recall. So the strategy is geared around delivering the shift from vision care to the connected eHealth. We have implemented a completely new organizational and operative model. And here I want to emphasize the big revamp of the organization in the USA. That includes all the functions. And of course, especially the US sales and marketing department. We organized the whole team now in a totally different way into three regions. Then new team members are also in place. It is self-evident that this is having a slight impact on the sales performance in the USA. But the reason we did this is, of course, that it enables us to grow in the long run. The third topic is what I mentioned already regarding the organization and related changes there, which are, of course, having an impact on the opex side, especially in the USA. We have been able to advance the integration extremely well on that front. And as of today, looking at Q4. We still have actions ongoing regarding the OpEx activities, but bit by bit, the focus is starting to move more towards harnessing the commercial synergies. Then our net debt to EBITDA ratio was quite high, a bit over five. We have been working, of course, during Q3 to secure the rights issue, which was oversubscribed. So that went well. And after the review period, the leverage is now reduced to a bit more than three. But Jukka is coming back to this one. And if we now start to look at Q4, we can see where the focus currently is. We still have activities and actions in our plans regarding the OpEx synergies, but we are shifting our focus a bit more now. Also the focus to harness the forthcoming commercial synergies. And what I mean with this is that we already have clear active cross-selling plans in place, and we are starting to execute them. We have plans on how to optimize the sales channels globally, so the US part is done. And then, of course, we are putting more emphasis on key account coverage as we now have a much wider product portfolio. With all these actions, we really have a feeling that we are having good momentum for 2027 as well. We have discussed many times in these calls whether there are new products coming, how we are allocating capital, and this is the latest case on that front. So during the Q3, we launched a new iCare tonometer called. iCare IC1000. Extremely well received among the distributor partners. And then, of course, our clinical clients. So we introduced the GuideCam alignment. So you have an excellent alignment feature, including the full-on automation and the camera on the screen. Then, of course, the SmartCradle allows wireless connectivity to clinical workflows, utilizing the same technology as the previous model. It is anesthesia-free, uses the rebound technology, and will in the long run also enable increased consumable sales. And then if you also look to the future. So, the strategy is not going to change. So in the product categories, what we have now as a combined company. We are going to continue to invest in the future in R&D in order to bring new innovations to the market. But this is the latest product which we launched during the Q3. But let's jump to the financials. So, over to you. Thank you, Jouni. Let's move to the key figures. And as a reminder, this is the first quarter where we have the full Visionix integration in our numbers, starting from the beginning of the quarter, as we only had one month of their results in the second quarter. But when looking at net sales, net sales growth with the reported numbers, like Jouni highlighted, was almost 130%. So net sales have more than doubled when you look at the quarterly numbers. Also, when looking at year-to-date numbers of 125 million, net sales are also growing by almost 60%. So the scale is totally different. Also, when looking at the companies and comparables, we are quite a different company nowadays than one year back as you can see, when looking at the profitability metrics, reaching an adjusted EBITA of €8.7 million compared to €6.6 million in quarter three, 2025, which is 14.7% of net sales compared to 25.7% in the comparable period. It is good to note that in absolute terms, this adjusted EBITA is more than 30% up when looking at the real euros. The new scale is also seen in our earnings line. And then when looking at the leverage metrics and balance sheet metrics, the equity ratio is 32% and gearing is 149%. And this is, of course, before the rights issue took place in October, because we report the quarterly numbers, but still sequentially. Also, the leverage metrics were improving and the balance sheet strengthened between the quarters. So that is really relevant as well. Then let's go into more detail regarding the net sales and net sales growth. So, quarter three net sales were €58.8 million. When we look at it organically, this means we compare it to the pro forma figures for the combined company from the third quarter of 2025. Our growth was basically flat, even looking at the third quarter year-to-date. But when looking under the numbers in different regions, we had a really strong performance in EMEA and Latam. And when we look at it organically, it had really strong growth driven by the big countries, Italy, France and our global customers as well, and supported by this multimodal offering. We have a strong overall offering. And then, like Jouni highlighted, the challenging market environment has continued in the DACH region and in North America. The reorganization we did impacted the sales numbers during the quarter. Three, 2026. And then let's look more in detail. Our profitability and adjusted EBITA, starting maybe first from the gross margin. So gross margin declined to 63.2% compared to 71.5% one year back. And it has a nine percentage point dilution impact coming from the Visionix lower margin profile. So now we have Visionix in our whole quarter numbers. And that is visible also in the gross margin numbers, as you see. And then a few other items impacting our profitability and gross margins. Still, the unit cost increases regarding the electronic components had a negative impact on our gross margin overall and also our sales mix. So those two together had around a 2 percentage point negative impact on the gross margin. But then at the same time, we had a positive impact coming from the North America business and tariff refunds overall. There was around a three percentage point positive impact on our gross margin for the quarter. As I highlighted previously, adjusted EBITA was €8.7 million for the quarter compared to €6.6 million in the comparable period. So roughly more than 30% up in earnings when looking at the adjusted EBITA line. And then let's move to the cash flow. Cash flow from operations turned positive for the third quarter at €5.5 million. And improved from the last year. Reported numbers in quarter three were €3 million. And that was driven by the strong working capital development during the quarter. And even though it included around 2 million in one-off payments regarding our integration, which is, of course, ongoing. And when looking more in detail at the balance sheet, of course, the balance sheet metrics are reflected by the Visionix acquisition. When looking at the third quarter situation, we had a term loan of 130 million. A vendor loan of 17 million euros. At that moment, we still had the bridge-to-equity facility of €80 million. So around 232 million net debt at the end of the quarter. Three. But still, our net gearing improved from 159% at the end of Q2 to 149%, and also the equity ratio went up from 31% at the end of Q2 to 32%. We had cash balances of €17 million at the end of the quarter. And also, this net debt to adjusted EBITDA ratio went down from 5.3. End of quarter 2 to 5.1. So all the balance sheet metrics improved even though this rights issue was not completed. When we look at the situation at the end of September. And when we look at the situation now, during October we were able to close the rights issue, which was fully oversubscribed. And by the way, thanks to everyone who joined the rights issue. And we have already, as of today, paid out the bridge to equity facility of €80 million. But of course, when we report these Q3 numbers, those are not yet visible here. And overall, we continue our profitable growth. We also improve our cash flow, which will improve the leverage metrics for the coming quarters and going forward. Then, regarding our shareholders' register at the end of September, maybe I will highlight a few points here regarding the Visionix acquisition. There are a few new names in the table coming from France, with Caravelle Capital SAS as a new owner owning more than 5% of the company. Also, Marc Abitbol became an owner, owning 1.5% of the company. Regarding the Visionix acquisition and, of course, overall, we have almost 50% of our owners outside Finland, which is quite a good number for a listed company. Money overall. And then let's go to our financial guidance. We have specified our financial guidance regarding net sales, and we have narrowed down the top end of the guidance. Our previous financial guidance for the net sales was between 190 million and 205 million. Our specified guidance is between 190 million up to 200 million. Regarding profitability, our guidance remains unchanged. And the changes are coming from the regional impacts. As we commented, we saw strong performance in Latam, but the reorganization in North America impacted our sales in the third quarter. And the challenging market environment continues in the APAC region. So all these are reflected in our new guidance. Thank you.

Jouni Toijala
17:37 - 17:41

Thank you. Jukka, let's move to the questions, please.

Operator
17:42 - 17:59

If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Nico Ruokangas from SEB. Please go ahead.

Nico Ruokangas
18:01 - 18:42

Hello, this is Nick from SEB. Thank you for the presentation. I have a couple of questions. And first of all, I wonder if you can give us a bit more color on organic growth. So, were sales flattish in both the legacy Revenio Group Corporation and Visionix, or were there significant differences? At least you hinted in the Q2 call, which was quite late already in Q3, that Revenio organic growth had started to pick up. So can you give a bit more color on that, please?

Jouni Toijala
18:43 - 22:20

As you actually said, Nick, both were flattish, and here I want to emphasize the logic. We made a fundamental change in the USA, as you mentioned, with strong growth in Europe, Middle East, Africa, and Latam; there was strong growth there. Then the APAC region remained a bit softer. And then we reorganized the whole US sales and marketing. We changed the regional setup. We even changed the scope of the area for the sales teams. We introduced the combined product portfolio. We cross-trained the US sales and marketing team to sell and market the full new combined company product portfolio. That is the logic, and I am happy to see that it was only a minor impact. We prioritized this activity right away after the 60 days. So the new organization setup was in place beginning of August. The reason why we prioritized this was all the other US-specific activities to guarantee a successful start for the integration, achieving the 5 million run rate, EBITDA uplift in terms of the opex, and gearing for future growth. We would have been able to perform better in the USA from a sales perspective if we hadn't changed anything, but that would not have been positive for long-term sustainable growth in the USA. Sorry for the long answer, but I think this is crucial. This is crucial to understand and still building. What I was saying is that the Revenio Group is now totally different than it used to be. Before or during the big part of Q1 and almost the whole of Q2. So, we are a totally different company. The focus for Q3 hasn't only been how do we maximize the organic growth for tonometers? How do we maximize the organic growth for imaging and perimetry? The focus has been on how we create a combined company strategy. How do we create and specify a new organization and operative model? How do we ensure that the rights issue is going to be successful? And how we kick off the promised 20 million synergy activities. I am happy to see that in this big shift and the big integration we started. So we are in a way flat. And the benefit is that we have been able to achieve the first 5 million in terms of synergies. Sorry for the long answer, but I think this is the big picture of how we see this internally at Revenio Group Corporation.

Nico Ruokangas
22:22 - 22:42

Yeah. Thanks. Very good. I see it is reasonable. So, does it mean that the negative impact came quite late in Q3? And we expect that to continue in Q4. Or how have you planned that?

Unknown 1
22:42 - 22:43

Yes, I would say.

Jouni Toijala
22:43 - 23:25

In terms of the US, we planned this during Q2, and then we started to execute during June and July. And then your new team was in place. This includes sales and marketing, finance, control, and HR. So the whole new US team was in place starting 1st of August, and then the team was ready to execute. So the team has been working to build the plans and continue on sales and focus on customers. . This has been the timing.

Nico Ruokangas
23:27 - 23:53

Okay. Understood. Thanks. Then on the larger customers you have mentioned, you have in the pipeline. Have you recognized any of those as sales yet? And was this NHS deal you mentioned in the report one of those that were in the pipeline? Can you provide more detail and an update on the large customer pipeline?

Jouni Toijala
23:53 - 24:13

Yeah. Yes, that deal was in the pipeline. Then, of course, we had a couple of other deals. Those have been moving forward and we are starting the rollout, toward early 2027.

Nico Ruokangas
24:15 - 24:28

Okay. So, regarding the NHS deal. So have you recognized sales from that in Q3? And if not, can you provide a bit more color on when we might see that?

Jouni Toijala
24:28 - 24:34

No, we have not recognized the revenue from the NHS deal for Q3.

Nico Ruokangas
24:36 - 24:42

Okay. Okay. And can you give any color on the size or timeline?

Jouni Toijala
24:42 - 24:48

No. I cannot comment on the specific size, but we are receiving orders bit by bit. We are starting to receive the orders.

Nico Ruokangas
24:50 - 25:29

Okay. Thank you. Then, last from me at this point, on tariff repayments, you indicated I guess some €2 million you received in Q3. Can you explain further which period those payments relate to? Those were the payments from early 2026, or does this include also tariff payments from 2025? And have you received all the tariff repayments you will receive overall as of the end of Q3, or should we expect more still in Q4?

Jukka Kainulainen
25:29 - 25:58

Yeah. What I can comment is that it related to earlier periods. The refunds come in, and we, of course, work constantly to secure more of them. But there is always significant uncertainty regarding those. So we don't plan, and we don't forecast generally when we achieve it or when we succeed in it. So, this is the level we can comment on, but it was really great to get it during the third quarter.

Nico Ruokangas
26:00 - 26:04

All right. Great. Thank you. That is all from me at this point.

Jukka Kainulainen
26:05 - 26:06

Thank you.

Operator
26:09 - 26:13

The next question comes from Daniel Lepisto from Danske Bank. Please go ahead.

Joni Sandoval
26:16 - 26:44

Hi, it is Daniel Lepisto from Danske Bank. I also have a couple of questions. Maybe starting off with the guidance, you cut the top line a little bit. I am a bit curious about where the negative delta came from. So was it this reorganization that happened in North America? Did it? Did it go as you planned, or was it about these larger deals slipping forward? So can you dissect this guidance top line a little bit?

Jouni Toijala
26:45 - 27:29

Maybe you can comment a bit further. But I think what we have been trying to improve, based on the feedback we have received, is that we usually have been guiding the top line based on the objective and the bottom line based on the objective. Now we have included the euro bracket for that one. And now, we are also trying to be more specific as the year comes to an end so that the transparency increases. So I think this is the underlying logic. Why we now have a bit more narrow range, and maybe you can comment.

Jukka Kainulainen
27:29 - 27:29

Yeah.

Jouni Toijala
27:29 - 27:31

And then on that.

Jukka Kainulainen
27:31 - 27:32

Yeah.

Jouni Toijala
27:32 - 27:34

Moving on to the next topic.

Jukka Kainulainen
27:34 - 27:58

As we commented, the APAC region continues to face a challenging situation, impacting sales in the third quarter, alongside the North American reorganization. That has an impact on our sales in H2. So those were the impacts driving down the top end of the sales guidance.

Joni Sandoval
28:01 - 28:17

Okay. Then, maybe still on this reorganization. So just to clarify, are you seeing any risks? What comes to this, seasonally, very important. Q4, so are you seeing any risks with this reorganization impacting the Q4 numbers still?

Jouni Toijala
28:17 - 29:20

And not from the reorganization point of view? That was also the reason why we moved really fast by reorganizing the teams globally, including in the USA, to put everything in place in order to be efficient for Q4, and I have to say and emphasize here that the organizational change in the USA and in other parts has been going extremely well and smoothly. No key people have left, and we have a US team fully functional for almost two months. So no worries on that one. So everything has gone well, but of course it has had an impact on our activities. But to sum up, I would still emphasize that from the reorganization point of view, the house is in very good order for Q4.

Joni Sandoval
29:24 - 29:42

Okay. That is good. Then regarding the gross margin, how have component issues impacted the gross margin? So is this going to roll over, has the situation worsened, or is this going to remain intense? How would you characterize this component issue?

Jukka Kainulainen
29:43 - 29:57

Yeah. So far, this will, of course, also impact the fourth quarter at least. So next year, we cannot, of course, comment, but it will continue also during the end of the year.

Joni Sandoval
30:00 - 30:22

Okay. That is clear. Then a final question on this capital expenditure. So can you give us some guidance on what kind of underlying capital expenditure run rate we should expect for this combined entity going forward? And then regarding these one-off costs that will be CapEx items. So when are these going to materialize?

Jukka Kainulainen
30:23 - 30:50

Yeah. So of course, the CapEx is now slightly higher, even though it remains at a reasonable level. Level. But regarding Visionix. We also have the real manufacturing. That is driving the level up. So you can use the third quarter as a baseline in your overall planning. And what was the other question you had on this?

Joni Sandoval
30:50 - 30:52

One-off costs.

Jukka Kainulainen
30:52 - 31:01

Yeah. At the moment, we are not planning to capitalize the one-off costs or integration-related IT costs.

Joni Sandoval
31:03 - 31:05

So it is something for maybe 2027.

Jukka Kainulainen
31:06 - 31:13

Yeah. 2027 will be part of our integration there. These are related opex investments. We do.

Joni Sandoval
31:16 - 31:18

Okay. That is all from me. Thank you.

Jouni Toijala
31:18 - 31:19

Thanks, Daniel.

Operator
31:23 - 31:28

The next question comes from Pia from Carnegie. Please go ahead.

Pia DNB
31:30 - 32:00

Hello, this is Pia from DNB Carnegie. Thank you for taking my questions, and thank you for the presentation and the really good questions from my analyst colleagues. I have a few follow-ups just to clarify. So as of now, do you see a risk of that? Your reorganization elsewhere will impact sales as negatively as it did in the US now in Q3?

Jouni Toijala
32:01 - 34:13

Uh, no. I think we have to remember the slight differences. Now, if you think of the USA and the remaining parts of the geography. So we had an old revenue model, where we had a direct sales force plus the reps, which are under our control. The same applies to Visionix. That needed to be reorganized right away in order to be fit for long-term growth in the USA, and in order to sell the combined portfolio, we needed to do the cross-training to enable and execute the cross-sales plans and have a combined company approach right away to address these big customer accounts. Then, if we go to the other parts of the region, such as Europe, Middle East, Africa, LatAm, and APAC. That is a combination of distributors, both from Visionix and from the legacy Revenio iCare side, as well as the direct sales countries. In a way, from the sales perspective, it is a much more natural setup. It is not as complicated to handle. So, what is going to happen there? We have already made certain alignments within the direct countries, creating plans on how to more efficiently work with distributors, consolidating certain distributors, or changing them based on the plans. I think it is good to understand that there is a slightly different setup in other parts of the world compared to the USA. In one sentence, we have good plans now also in other parts of the world. And those are under execution.

Pia DNB
34:16 - 34:33

All right. Thank you. Then, regarding your cross-selling wins, are there any? Have you started to see some kind of cross-selling wins now? Already in Q3.

Jouni Toijala
34:34 - 35:04

Not yet too much in Q3, but the pipeline is building. Yes. I think that's a key point to understand that we have started to build the pipeline, perform the cross training in the areas where it is needed, and plan the cross sales activities.

Pia DNB
35:06 - 35:40

All right. Thank you. And then in the report, you shared some rough numbers or sales split on pro forma sales for 2025 by product line, and regarding that, I would like to understand the OCT sales you refer to. What does that contain and are there any overlaps in that OCT category with, for example. The imaging devices.

Jukka Kainulainen
35:42 - 35:57

Yeah. So that is the OCT sales and the product line. We acquired this in connection with the Visionix acquisition. Visionix acquisition. And maybe you can comment regarding the overlaps with our old iCare imaging products. Old iCare imaging products.

Jouni Toijala
35:58 - 36:07

Yeah. No, no. That is a pure OCT business. No overlap with the eye care imaging business.

Pia DNB
36:10 - 36:33

Uh, all right. Thank you. And then I think in conjunction with the acquisition, you also explained that part of Visionix sales were. Oh. Sales. Right. So how does that fit? Can you share some more information about the OEM sales? What kind of products? Uh, yeah. What does that involve?

Jouni Toijala
36:34 - 37:33

Yeah. So, the big part on that front is the VX series as an example, VX series. The 650 multimodal devices and that part of the OEM business are going to continue to be in our focus. And really the reason is that the clients are extremely big players who are bundling the multimodal devices, as an example, with IOLs or so forth. So that is still going to be a good and significant business for us. Also, in the long run, those are customers that we are not able to reach otherwise. So, quite a lot of bundle deals with the IOLs, as I said, and links to the multimodal side of the business.

Pia DNB
37:35 - 37:38

All right. That is all for now. Thank you.

Jouni Toijala
37:38 - 37:40

Thank you. Thank you.

Operator
37:42 - 37:46

The next question comes from Joni Sandoval from Nordea. Please go ahead.

Jukka Kainulainen
37:48 - 37:49

Yeah. Thanks, John.

Joni Sandoval
37:50 - 38:00

A couple of questions also from my side. Any update on your iCare IC1000 FDA approval process and related costs? When should we expect this to happen?

Jouni Toijala
38:01 - 38:56

Yeah. Pivotal studies have been completed with some minor fine-tuning. Now the algorithm is looking to start the clinical studies on that front. Um, costs 27. I think we are sliding towards Q3 or Q4 2027, with the approval timing slightly sliding forward. On a positive note, we now have Doctor's Plus approved together with the iHealth screen algorithm. So, in a way, we are good to go in the USA. What comes to Doctor? Screening. But then of course, the software partner is different compared to our own because it is an iHealth screen, but that is currently the status on that side.

Joni Sandoval
38:58 - 39:15

Okay. Thanks. And then maybe a couple of technical questions for Jukka. Net financial items were at break even. Could you open up a little bit the logic behind this and what is actually your current average interest rate on the loan portfolio?

Jukka Kainulainen
39:15 - 39:54

Yeah. So regarding interest costs. Quarter three interest costs were 1.8 million. But then we also have this interest rate swap for the term loan. So about half of that has been hedged. So that has quite a big positive impact now. Now in the third quarter. So, it was actually more than a 1.4 million positive impact. And we also have an intercompany loan in USD from our entity in Europe to the US of around 30 million. So that had a positive impact as well. Well, that is why it looked quite good when looking at the finance income and expenses.

Joni Sandoval
39:56 - 40:10

Okay. That's clear. Second technical question on the deferred tax assets that you have in the balance sheet: should we expect the effective tax rate to remain low in Q4, and how do you expect this to evolve in 2027?

Jukka Kainulainen
40:11 - 40:36

Yeah. So this is something we are working on at the moment. Overall, the transfer pricing is impacting the tax rate. But of course, overall, we will try to keep it competitive also for the next year. I do not foresee any changes for the fourth quarter or next year, but this is something we work on constantly at the company level.

Joni Sandoval
40:37 - 40:39

Okay. Thanks. That is all for me.

Jouni Toijala
40:39 - 40:40

Thank you Tony.

Jukka Kainulainen
40:40 - 40:41

Thank you.

Operator
40:43 - 40:57

There are no more questions at this time. So I hand the conference back to the speakers. Maybe the next question comes from Nico Ruokangas from SEB. Please go ahead.

Nico Ruokangas
40:59 - 41:39

Hello. Thank you. This is Nicolas again. One more additional question on the cybersecurity issue. You reported this earlier this week. So, could you provide comments on what the implications are? Does it have any kind of financial or operational impact on you? Do you see any need for further investments into Visionix cybersecurity in the software platform? Thanks.

Jouni Toijala
41:40 - 43:10

So, um, uh, yes. Entry was made to one internal server, which did not include any IP or anything of that nature. No patient data was involved. The case is already in order. And then if we look at the hardening and how to improve the cybersecurity. That was already baked into the integration plan to strengthen Visionix's cybersecurity and IT infrastructure. So those costs are already baked into the original plan. To summarize in one sentence. Yes. Someone gained access to one server, but there was no impact on operations, no impact on the financial performance, and no loss of intellectual property. So in that sense, our house is in order. But we wanted to be transparent on this one so that you hear it from us first and not include any rumors. That was also the logic behind why we issued the press release. And of course, it was not a stock exchange release because we do not see a significant impact from this incident. So that's the background. And that is the logic for the press release.

Jukka Kainulainen
43:10 - 43:25

And naturally, all the companies. We also definitely see cybersecurity as a really critical point and high on the agenda. And of course, we will continue investing in that to maintain a strong environment and good processes as well.

Nico Ruokangas
43:27 - 43:33

Okay. Thank you. That was a good answer. It sounds reasonable. Good to hear. Thank you.

Jouni Toijala
43:33 - 43:34

Thank you. Thank you.

Operator
43:37 - 43:42

There are no more questions at this time. So I hand the conference back to the speakers.

Jouni Toijala
43:43 - 44:00

Thank you very much for your time. Thank you for the excellent questions and have a nice autumn. And we will return after the Q4 results are ready. I think you are right. So it will be around mid-February.

Jukka Kainulainen
44:00 - 44:05

Mid or end of February. But we will communicate it via a stock exchange release.

Jouni Toijala
44:06 - 44:09

Thank you all. Have a good rest of the day.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…